StockUS listing USOPHLYPINKHealthcareDeep Value

Ono Pharmaceutical Co Ltd(OPHLY) Stock Analysis | Healthcare

USD --+0.00%
Reward57Moderate
Risk11Low
75%Data
3.1% dividend yield
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 8.00Bn
Reward Ratingⓘ57 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ11 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on OPHLY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Ono Pharmaceutical Co Ltd?

produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide.

AI Brief Pro

The brief on Ono Pharmaceutical Co Ltd

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Ono Pharmaceutical Co Ltd?

produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 8.00B, and a P/E ratio of 23.4x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (57)

Similar stocks to compare

A short list of Drug Manufacturers - General names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - General
P/E Ratio23.4167
Beta0.044
Insider Activity
12M windowNo data
No insider activity data available for this ticker.